Skip navigation
Please use this identifier to cite or link to this item: http://repositorio.unb.br/handle/10482/25425
Files in This Item:
File SizeFormat 
0750.pdf207,02 kBAdobe PDFView/Open
Title: Tratamento da forma mucosa de leishmaniose sem resposta a glucantime, com anfotericina B liposomal
Authors: Sampaio, Raimunda Nonata Ribeiro
Marsden, Philip Davis
Assunto:: Leishmaniose mucosa
Leishmania (Viannia) braziliensis
Anfotericina B liposomal
Mucosal leishmaniasis
Leishmania (Viannia) braziliensis
Amphotericin B liposome
Issue Date: 1997
Publisher: Sociedade Brasileira de Medicina Tropical - SBMT
Citation: Rev. Soc. Bras. Med. Trop.,v.30,n.2,p.125-128,1997
Abstract: Tratamos com ambisome (2 a 5g totais de dose) seis pacientes com leishmaniose mucosa sem resposta a tratamento com glucantime (20mg SbV/kg/dia). A dose diária usada foi 2 a 3mg/kg/dia, aplicada por um mínimo de 20 dias. Após 26 a 38 meses de acompanhamento, cinco pacientes estão clinicamente curados. Um recidivou aos 6 meses. Não foram observados efeitos colaterais além de cefaléia, após a injeção. O ambisome constitue uma opção terapêutica para os pacientes com leishmaniose mucosa sem resposta aos antimoniais.
We treated six patients with mucosal leishmaniasis who failed to respond to glucantime (20mg/kg/day) with ambisome (2-5 grams total dose). The daily dose was 2-3mg/kg/day given for a minimum of 20 days. After 26-38 months of follow up, five patients were clinically cured. One relapsed after six months. No side effects of therapy were observed apart from headache after injection. Ambisome is a therapeutic option for patients with mucosal leishmaniasis unresponsive to antimonials.
DOI: https://dx.doi.org/10.1590/S0037-86821997000200007
Appears in Collections:Uso interno - em processamento

Show full item record Recommend this item " class="statisticsLink btn btn-primary" href="/handle/10482/25425/statistics">



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.